News
In study MP4001, 49.1% of patients treated with Dymista achieved a clinically significant 50% improvement in rTNSS (Total Nasal Symptom Score).
Dymista will be available in the US during the second half of 2012. For more information call (732) 564-2200 or visit www.medapharma.us.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results